Clinical Trial Update: An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD) [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating multiple doses of cannabidiol to prevent acute graft-versus-host disease (aGVHD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Kalytera Therapeutics Israel, Ltd. | Conditions: Prevention aGVHD | Phase 2 | Status: UNKNOWN